6.5 C
New York
Thursday, October 21, 2021

Mixing COVID vaccines is a “dangerous trend” – warns WHO

Must Read

Chronic Pain: New painkiller technique without side effects and drug addiction

Innovative non-pharmacological pain management practice developed by scientists - This is how the technique works

Experts identify a new drug that can help diabetic patients recover faster after heart attack

A new study by the University of Oxford's researchers has found a drug that may help repair heart function in...

Study says this drink could reduce death risk from chronic liver disease by 49%

Chronic liver disease is also known as the progressive reduction of liver function over a period of...
Kamal Saini
Kamal S. has been Journalist and Writer for Business, Hardware and Gadgets at Revyuh.com since 2018. He deals with B2b, Funding, Blockchain, Law, IT security, privacy, surveillance, digital self-defense and network policy. As part of his studies of political science, sociology and law, he researched the impact of technology on human coexistence. Email: kamal (at) revyuh (dot) com

The World Health Organization’s chief scientist on Monday warned against mixing and combining COVID-19 vaccinations from various manufacturers on, calling it a “dangerous trend” because of the lack of evidence on the health consequences.

“It’s a little bit of a dangerous trend here. We are in a data-free, evidence-free zone as far as mix and match,” in an online briefing, Soumya Swaminathan said.

“It will be a chaotic situation in countries if citizens start deciding when and who will be taking a second, a third and a fourth dose.”

Last month, one study from researchers running the University of Oxford-led Com-COV study, revealed that mixing the AstraZeneca and Pfizer coronavirus doses induces an effective immune response against COVID-19.

In the study published on the Lancet pre-print server, scientists reported that both “mixed” schedules (Pfizer-BioNTech followed by Oxford-AstraZeneca, and Oxford-AstraZeneca followed by Pfizer-BioNTech) generated high concentrations of antibodies against the SARS-CoV2 spike IgG protein when doses were administered four weeks apart.

In May, researchers reported preliminary Com-COV data revealing more frequent mild to moderate reactions in mixed schedules compared to standard schedules, however, these were short-lived in duration.

Photo by FABRICE COFFRINI/POOL/AFP via Getty Images

- Advertisement -
- Advertisement -

Latest News

- Advertisement -

More Articles Like This

- Advertisement -